NCT02941783View on ClinicalTrials.gov

Drug Use Investigation of Kovaltry in Hemophilia A Patients

CompletedOBSERVATIONAL
Enrollment

230

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

March 23, 2022

Study Completion Date

September 16, 2025

Conditions
Hemophilia A
Interventions
DRUG

Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)

Treatment parameters following the physician's decision based on the summary of product characteristics.

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT02941783 - Drug Use Investigation of Kovaltry in Hemophilia A Patients | Biotech Hunter | Biotech Hunter